Aquestive Therapeutics (NASDAQ:AQST) CEO Daniel Barber Sells 25,000 Shares of Company Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 25,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the sale, the chief executive officer owned 627,317 shares of the company’s stock, valued at approximately $2,647,277.74. This trade represents a 3.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

• On Tuesday, September 15th, Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock. The stock was sold at an average price of $4.82, for a total value of $120,500.00.

Aquestive Therapeutics Trading Down 6.9%

NASDAQ:AQST traded down $0.28 during mid-day trading on Friday, reaching $3.78. 5,245,984 shares of the stock were exchanged, compared to its average volume of 2,138,648. The business has a fifty day moving average price of $4.74 and a 200 day moving average price of $4.35. The firm has a market capitalization of $474.43 million, a PE ratio of -5.82 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 1-year low of $2.93 and a 1-year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. On average, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.50 earnings per share for the current year.

Trending Headlines about Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: The FDA accepted Aquestive’s resubmitted New Drug Application for Anaphylm, its investigational sublingual film for severe allergic reactions and anaphylaxis. The filing was deemed complete, with a PDUFA action date of March 16, 2027. If approved, Anaphylm could become the first oral rescue treatment for anaphylaxis, significantly expanding AQST’s commercial opportunity. Aquestive Therapeutics Announces FDA Acceptance of Anaphylm NDA Resubmission
• Positive Sentiment: The resubmission reportedly includes improved human-factors data showing a substantial reduction in packaging and administration errors, addressing previous FDA concerns. One analyst upgraded AQST to Buy and projected potential Anaphylm revenue exceeding $250 million annually by 2030, although competition and reimbursement remain risks. Aquestive FDA Acceptance of Anaphylm Resubmission Makes for Rating Upgrade
• Neutral Sentiment: AQST CEO Daniel Barber sold 25,000 shares for approximately $105,500, reducing his direct position by 3.83%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a discretionary bearish signal. SEC Insider Transaction Filing
• Negative Sentiment: Options trading was unusually defensive, with investors purchasing 11,658 put options—about 390% above typical volume—suggesting increased hedging or bearish speculation around AQST.

Analyst Ratings Changes

AQST has been the subject of several recent research reports. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $210,000. Engineers Gate Manager LP increased its stake in Aquestive Therapeutics by 20.5% in the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock worth $207,000 after purchasing an additional 8,496 shares in the last quarter. Wedbush Securities Inc. acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth about $60,000. Wellington Management Group LLP raised its holdings in Aquestive Therapeutics by 4.0% during the 2nd quarter. Wellington Management Group LLP now owns 301,647 shares of the company’s stock worth $1,255,000 after buying an additional 11,587 shares during the period. Finally, Beacon Pointe Advisors LLC acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth about $252,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.

Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.